AUSTIN, Texas–(BUSINESS WIRE)–Texas Original, Texas’ leading medical cannabis provider, announced that Kelly Roland has been promoted to president. Roland served as Texas Original’s senior vice president of sales and chief revenue officer for three years. During that time, she oversaw and drove the company’s rise to its commanding leadership position in Texas’ growing cannabis market. … [Read more…]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) will reconvene to review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]) for the treatment of amyotrophic lateral sclerosis (ALS). The second … [Read more…]
Research Evaluates Effects of Against the Tumor Microenvironment MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a Joint Research Collaboration Agreement has been established with the Universities of Jaén and Granada, Spain. Since late … [Read more…]
EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a study in Nature’s Scientific Reports entitled “Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma”. The study was led by Dr. Cheng Liu, President and Chief … [Read more…]
PARSIPPANY, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Keith Westby, Chief Operating Officer, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022, at 1:45 p.m. Eastern Time. Investors and the general public are invited to access the … [Read more…]
Second-Quarter 2022 Results: — Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million — — GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million — — TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million — — KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Million — — Cash Position of … [Read more…]
FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, Aug. 10, 2022, … [Read more…]
Atlas’ stealth-stage company will leverage AbCellera’s technology to start and advance new drug programs with enhanced speed and capital efficiency VANCOUVER, British Columbia & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$ABCL—AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage … [Read more…]
– Expect to complete SER-109 Biologics License Application filing in the coming weeks – – Reported confirmatory SER-109 Phase 3 study results, including in individuals with a first recurrence of C. difficile infection – – Strengthened balance sheet with $100 million registered direct equity offering – Conference call at 8:30 a.m. ET today – CAMBRIDGE, … [Read more…]
– Second-Quarter Revenue of $973.1 Million – – Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77 – – Reduces 2022 Guidance – WILMINGTON, Mass.–(BUSINESS WIRE)–$CRL #CRL–Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2022. For the quarter, revenue was $973.1 million, … [Read more…]
